Efforts have been made to differentially diagnose IBD from functional bowel disease, monitor disease activity, and predict therapeutic effect, recurrence, prognosis by blood and stool tests, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and fecal calprotectin (8–11). This evidence concerns the gene CRP and inflammatory bowel disease.